Free lookups: 2/3 Unlock Pro
Clinical reference Find a medicine
Ctrl K
2 of 3 free lookups remaining Upgrade
New search Medicine profile chlorpheniramine mal. 4mg, pseudoephedrine Hcl 30mg, paracetamol 350mg, caffeine 30mg

Clinical medicine profile

chlorpheniramine mal. 4mg, pseudoephedrine Hcl 30mg, paracetamol 350mg, caffeine 30mg

Non-opioid analgesic / antipyretic

POM
Evidence state Source not available Reviewed 14 Aug 2026
Route
ORAL / RECTAL / IV
Schedule
POM
ATC
Not assigned
PPB status
registered
Patient advice Check interactions
Verification required

This profile needs source confirmation

A traceable source link is not attached to this profile. Confirm prescribing decisions against the current SmPC and Kenya STG/EML.

01 Risk first

Safety essentials

The information most likely to change a prescribing or dispensing decision.

Contraindications

  • Severe active hepatic disease / acute liver failure.
  • Hypersensitivity.
  • Chronic heavy alcohol use — use reduced maximum daily dose or avoid.

Precautions

  • Do not exceed 4 g/day in adults (lower in malnutrition, alcohol, elderly, liver disease — often ≤2–3 g).
  • Account for combination products (cold remedies).
  • Overdose is a medical emergency (NAC protocol).
02 Point of care

Dosing matrix

Population and organ-function guidance, shown together for faster comparison.

Adult

Dosing is indication-, age-, weight- and organ-function-specific for this INN. Do not use class averages for high-risk patients. Confirm the exact regimen in the current SmPC and Kenya Standard Treatment Guidelines. Typical professional workflow: (1) confirm indication, (2) check renal/hepatic function, (3) screen interactions/allergies, (4) select dose/route/duration, (5) define monitoring.

Paediatric

Paediatric dosing is weight- and age-based; use a paediatric formulary / SmPC. Do not extrapolate adult tablets without calculation.

Renal

Generally safe; prolonged high dose rare associations — prefer careful use in advanced CKD.

  • CrCl 0–120: Confirm renal dosing in product SmPC / primary label.
Hepatic

PRIMARY toxicity organ in overdose; therapeutic doses usually safe if daily limits respected.

03 Clinical use

Use, effects & interactions

Indications

  • Therapeutic use is agent- and indication-specific within the class (Non-opioid analgesic / antipyretic).
  • Use according to culture results, national guidelines (Kenya STG/EML where applicable) and the current product SmPC.
  • Relief of symptoms of cold and flu

Adverse effects

  • Rare at therapeutic doses.
  • Serious: acute liver failure in overdose, rare severe skin reactions (SJS/TEN/AGEP).
  • First-line for mild–moderate pain and fever.
  • Calculate total daily exposure from all sources.
  • In overdose: timed levels + NAC per protocol — do not wait for symptoms.
04 Pharmacology

Mechanism & disposition

Paracetamol inhibits central prostaglandin synthesis via effects on cyclo-oxygenase pathways (including COX-2 preferential central effects) and may engage serotonergic descending pathways.

Inhibit COX↓ ProstaglandinsAnalgesia / anti-inflammatory
Read complete mechanism

Paracetamol inhibits central prostaglandin synthesis via effects on cyclo-oxygenase pathways (including COX-2 preferential central effects) and may engage serotonergic descending pathways. Antipyretic effect via hypothalamic heat-regulating centre. Minimal peripheral anti-inflammatory action.

Onset

30–60 minutes oral

Duration

4–6 hours

Route

ORAL / RECTAL / IV

Metabolism

(glucuronidation/sulfation); toxic NAPQI pathway via CYP2E1 when pathways saturated or glutathione depleted.

Half-life

~2–3 h; prolonged in liver disease/overdose.

05 Special populations

Pregnancy, lactation & diet

Pregnancy

Analgesic/antipyretic of choice in pregnancy when needed; use lowest effective dose/shortest duration.

Lactation

Compatible with breastfeeding at standard doses.

06 Kenya market

Brands & loaded prices

From
Median
Listings0
BrandManufacturerPackObserved price
No reviewed brand listings are linked yet.
07 Provenance

Sources & review state

Primary sourceLocal active-ingredient clinical extract; Professional class pharmacology (Non-opioid analgesic / antipyretic)
Last reviewed14 Aug 2026
EvidenceSource not available

Decision support only. Confirm patient-specific decisions against the current product SmPC, Kenya STG/EML, and professional judgement.